Expert Discusses Approval of First CAR T-Cell Therapy – OncLive
OncLive |
Expert Discusses Approval of First CAR T-Cell Therapy
OncLive OncLive: Can you please provide some background on this CAR T-cell therapy? Ferrara: This is a therapy for relapsed leukemia. If a type of leukemia does not respond to chemotherapy, which happens around 25% of the time, it’s very unlikely to completely … Monroe Carell Jr. Children’s Hospital at Vanderbilt to offer new cutting-edge treatment for type of pediatric leukemiaWinchester Herald Chronicle |
Science Daily |
New assay leads to step toward gene therapy for deaf patients
Science Daily “We were trying to shorten the gene, to find a truncated form that can be used for gene therapy. There is a size limit in terms of what you can package into the gene delivery vehicle, and otoferlin is too large. That’s the holy grail, trying to find a … |
OncLive |
Kymriah approval generates questions about cost, access, long-term impact of CAR T-cell therapy
Healio The recent FDA approval of tisagenlecleucel T-suspension for the treatment of children and young adults with refractory B-cell precursor acute lymphoblastic leukemia marks the first-ever chimeric antigen receptor (CAR) T-cell therapy approval in the … Monroe Carell Jr. Children’s Hospital at Vanderbilt to offer new cutting-edge treatment for type of pediatric leukemiaWinchester Herald Chronicle |
|
Policeman donates stem cells to leukemia patient
Shanghai Daily (subscription) SIX years ago police officer Xu Miao had an encounter he never forgot. And yesterday it led to him becoming a donator of stem cells in Shanghai. The recipient of his stem cells will be a leukemia patient who lives in south China’s Guangxi Zhuang … |
Winchester Herald Chronicle |
Monroe Carell Jr. Children’s Hospital at Vanderbilt to offer new cutting-edge treatment for type of pediatric leukemia
Winchester Herald Chronicle This novel therapy, a personalized treatment known as chimeric antigen receptor (CAR) T-cell therapy, is an innovative treatment designed for children and young adults with pre-B cell ALL that has come back after treatment (relapsed) or unresponsive to … |
OncLive |
Practical Issues Surrounding Immunotherapy for HNSCC
OncLive Ezra Cohen, MD: Let’s talk about a couple of very practical issues. The first is a patient who has had prior cetuximab, and now you’re thinking about immunotherapy in the form of an anti-PD-1. Is there a reason to think about that patient any … |
Xconomy |
How Bayer and Ginkgo Teamed Up in a $100M Synthetic Biology Bet
Xconomy Nitrogen is essential for plant growth and photosynthesis, but plants can’t pull it directly from air. They rely on bacteria on their roots to convert the gas into a usable form. Many major food crops don’t have these bacteria but Bayer wants to change … |